Displaying 101–125 of 518 results for PAT
Readers recognize tools that break new ground but promise to improve efficiency
More than 20 on-demand webcast presentations from industry experts and leading solutions providers. NIR, Raman and Particle Characterization technologies and applications that are improving pharmaceutical product and process quality.
The companys manufacturing facility in Freiburg, Germany, uses an approach that maximizes flexibility and segmentation
Lets redefine PAT as the Practical Application of Technology
What would happen if everyone tried to patent good science, and the way to a good Design Space?
Real-time viable particle counters present clear opportunities for pharma, but also unique challengesamong them, the need to update regulatory guidance for Rapid Microbiological Methods.
Manufacturers are reporting fewer batch failures, adopting PAT and other quality initiatives, and stepping up supply chain quality control.
When it comes to QbD, we keep using that word, but does it mean what we think it means?
Solution providers churn out new and improved products in the heated market for upstream and downstream filtration technology.
Trade show consolidation can be a good thing, at least when it gives smaller innovator companies room to grow.
Can drug manufacturing reach its potential without standards, science and an admission that theres a need for improvement?
Standard work definitions, and recognized standards, will improve drug manufacturingnot nostalgia, or the insistence that pharma is different.
The big picture has changed very little in ten years. While pointing out root causes, observers also see reasons for optimism.
Assessing the cost of poor quality doesnt just prevent disasters; its good for business.
Analysts say that 2012 may prove to be pharmas most challenging year ever.
Modern control is the best way to ensure patient safety (and corporate survival).
Out-of-trend results from APRs offer unique insights into ingredients and finished products.
Changing from the status quo to meaningful testing will satisfy both FDA and ASTM.
For manufacturers who lack formulation and process knowledge, the benefits of getting to market fast can be outstripped by the costs of unexpected failures.
Effective change must improve business performance, and not just a process.
When the whole so closely resembles the individual parts, where is the big picture, or the path to continuous improvement?
When equipment and processes challenge solvent recovery for small-volume streams, an atypical approach is needed, says Pfizers Frank Urbanski.
In a recent talk, Ajaz Hussain, former FDA Deputy Director of the Office of Pharmaceutical Science (OPS), reminisces about the Agency's 21st Century initiative and looks ahead to challenges yet to be addressed.
Revived interest in SPC only heightens the need for new data architecture models
Authors from Pfizer and Rockwell Automation propose a closed-control scheme for pharmaceutical PAT.